IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended): A method of selecting a patient highly responsive to WT1 vaccine, comprising ~~the following steps~~ (a), (b) and (c):

(a) isolating a biological sample containing CTL precursor cells from a test subject;

(b) measuring the existence frequency or amount of WT1-specific CTL precursor cells of effector type in the biological sample of (a); and

(c) deciding whether or not the measured value of (b) is high by comparison with that of healthy subject, and evaluating the responsiveness to WT1 vaccine;

wherein the WT1 vaccine is a WT1 derived tumor antigen peptide that is originated from human WT1, is able to form a complex with an HLA antigen, which exerts HLA-restricted CTL activity.

2.-3. (Cancelled)

4. (Currently Amended): The method of selection according to claim [[3]] 1, which comprises ~~the following steps~~ (a), (b), (c) and (d):

(a) isolating a biological sample containing CTL precursor cells from a test subject;

(b) bringing an HLA tetramer comprising a WT1-derived tumor antigen peptide contact with the biological sample of (a);

(c) measuring the existence frequency or amount of WT1-specific CTL precursor cells of effector type bound to the HLA tetramer; and

(d) deciding whether or not the measured value of (c) is high by comparison with that of healthy subject, and evaluating the responsiveness to WT1 vaccine.

5. (Currently Amended): The method of selection according to claim 4, wherein ~~the step~~ (c) in claim 4 is carried out by measuring the proportion of HLA tetramer-bound cells among CD8-positive or CD8/CD3-positive CTL precursor cells.

6. (Currently Amended): The method of selection according to claim 4 ~~or 5~~ wherein the HLA antigen as a component of HLA tetramer is an HLA-A24 antigen or an HLA-A2 antigen.

7. (Currently Amended): The method of selection according to claim 4 ~~any one of claims 4 to 6~~, wherein the WT1-derived tumor antigen peptide is selected from the group consisting of ~~following peptides~~:

Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2),

Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3),

Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 4) and

Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 5).

8. (Currently Amended): The method of selection according to claim 1 ~~any one of claims 1 to 7~~, which is carried out using flow cytometry.

9. (Currently Amended): The method of selection according to claim 1 ~~any one of claims 1 to 8~~, wherein the responsiveness to WT1 vaccine is evaluated using as an indicator that the existence frequency or amount of WT1-specific CTL precursor cells of effector type is 1.5 times or higher compared to that of healthy subject.

10. (Cancelled)

11. (Currently Amended): The method of selection according to claim [[10]] 1, wherein measurement of the existence frequency or amount of WT1-specific CTL precursor cells of effector type is performed by a method selected from the group consisting of ~~which uses any one of~~ HLA monomer method, HLA dimer method, HLA tetramer method, HLA pentamer method, ELISPOT method, realtime RT-PCR technique and limiting dilution method ~~in the measurement of the existence frequency or amount of WT1-specific CTL precursor cells of effector type~~.

12. (Original): The method of selection according to claim 11, which uses the HLA tetramer method.

13. (Currently Amended): The method of selection according to claim 12, which comprises ~~the following steps~~ (a), (b), (c) and (d):

(a) isolating a biological sample containing CTL precursor cells from a test subject;

(b) bringing an HLA tetramer comprising a WT1-derived tumor antigen peptide, an anti-CD8 antibody, an anti-CD45RA antibody and an anti-CD27 antibody contact with the biological sample of (a);

(c) measuring the proportion of CD45RA-postive and CD27-negative CTL precursor cells of effector type among CTL precursor cells which are positive for CD8 or CD8/CD3 and positive for binding to HLA tetramer; and

(d) deciding whether or not the measured result of (c) is high by comparison with that of healthy subject, and evaluating the responsiveness to WT1 vaccine.

14. (Original): The method of selection according to claim 13, wherein the HLA antigen as a component of HLA tetramer is an HLA-A24 antigen or an HLA-A2 antigen.

15. (Currently Amended): The method of selection according to claim 13 ~~or 14~~, wherein the WT1-derived tumor antigen peptide is selected from the group consisting of ~~following peptides~~:

Cys Met Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 2),

Cys Tyr Thr Trp Asn Gln Met Asn Leu (SEQ ID NO: 3),

Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 4) and

Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 5).

16. (Currently Amended): The method of selection according to claim 11 ~~any one of claims 10 to 15~~, which is carried out using flow cytometry.

17.-62. (Cancelled)

63. (New): A method for identifying a human subject for treatment with WT1 vaccine, comprising:

(a) obtaining sample containing CTL precursor cells from a human subject having a cancer that expresses WT1;

(b) measuring the existence frequency or amount of WT1-specific CTL precursor effector cells in the sample of (a); and

(c) identifying a human subject for treatment with WT1 vaccine when the frequency or amount of WT1-specific CTL precursor effector cells is elevated compared to those in a health subject.

64. (New): The method of claim 63, wherein measuring the existence frequency or amount of WT1-specific CTL precursor effector cells comprises contacting the sample with the peptide of SEQ ID NO: 1 or a fragment thereof which is able to form a complex with an HLA antigen.

65. (New): The method of claim 64, comprising contacting the sample with a peptide fragment selected from the group consisting of SEQ ID NO: 2, 3, 4, and 5.

66. (New): The method of claim 64, comprising contacting the sample with a peptide fragment selected from the group consisting of SEQ ID NO: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.

67. (New): The method of claim 64, wherein the HLA antigen is HLA-A2 and the peptide is SEQ ID NO: 2 or SEQ ID NO: 4.

68. (New): The method of claim 64, wherein the HLA antigen is HLA-A24 and the peptide is SEQ ID NO: 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.

69. (New): The method of claim 63, wherein (b) comprises bringing an HLA tetramer comprising a WT1-derived tumor antigen peptide into contact with the sample of (a).

70. (New): The method of claim 63, which is carried out using flow cytometry.